NYSE:MDTMedical Equipment
Is Medtronic (MDT) A Bargain After Renal Denervation Optimism And Strong Revenue Growth?
Recent commentary on Medtronic (MDT) has focused on its cardiac ablation, diabetes care and hypertension franchises, with the FDA approved Symplicity Spyral renal denervation system drawing attention as investors weigh differing short term earnings views.
See our latest analysis for Medtronic.
Medtronic’s recent 9.71% 1 month share price return contrasts with a share price decline of 15.69% year to date and a 1 year total shareholder return decline of 2.80%. This suggests momentum has picked...